The Drugs Controller General of India (DCGI) has granted permission for emergency use of anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Laboratories (DRL), Hyderabad.
In his virtual address at the 25th meeting of the Group of Ministers, the Health Minister said, “180 districts have showed no fresh cases in the last seven days, 18 districts in 14 days, 54 districts in 21 days and 32 districts were bereft of any fresh cases in the last 28 days.” He said that across the country, the number of patients in ICU beds is 4,88,861 while 1,70,841 patients were on ventilators and 9,02,291 patients were on oxygen support.
Bombay High Court calls for more Remdesivir for Maharashtra
Updated:
Updated:
Share Article
A view of the Bombay High Court, in Mumbai. File
| Photo Credit:
Vivek Bendre
The Nagpur bench of the Bombay High Court on Friday requested the Drugs Controller General of India (DCGI) for more vials of Remdesivir for Maharashtra.
A Division Bench of justices Sunil Shukre and S.M. Modak was hearing a
suo motu public interest litigation on shortage of Remdesivir, oxygen and beds for COVID 19 patients.
The court asked, “Have new stocks been received on Remdesivir and oxygen? We have received information from several quarters that Remdesivir is not an elixir. How do we decide how much is required? We need details about medicines provided to other regions apart from Nashik.”
21,000 People Contracted Covid-19 After Receiving First Dose Of Vaccine: Centre outlookindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outlookindia.com Daily Mail and Mail on Sunday newspapers.
The development comes after DCGI (Drugs Controller General of India) gave its nod to foreign-made and approved COVID-19 vaccines following a massive spike in coronavirus cases